V260 Registration Study (V260-013)(COMPLETED)

Immunogenicity and Safety of V260 in Healthy Infants in Korea

Immunogenicity and Safety of V260 in Healthy Infants in Korea

Inclusion Criteria:

• At first study vaccination, age 6 weeks through exactly 12 weeks

Exclusion Criteria:

• History of congenital abdominal disorders, intussusception, or abdominal surgery
• History of known prior rotavirus disease
• Ongoing chronic diarrhea or failure to thrive
• Clinical evidence of active gastrointestinal illness